Browse our 650+ Publications​

Latest Publications

Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease

Parsons E et al.
Frontiers in Immunology
January 2026
Authors and Affiliates
Emily Parsons, Zhongyan Lu, Stephanie A. Richard, Amanda Zelkoski, Janifer Le, Naraen Palanikumar, Phuong Nguyen, Camille Alba, Gauthaman Sukumar, John Rosenberger, Xijun Zhang, Timothy H. Burgess, Rhonda Colombo, Katrin Mende, Catherine Berjohn, Nursat Epsi, Brian K. Agan, David Tribble, David A. Lindholm, Clifton L. Dalgard, Simon D. Pollett, Allison M. W. Malloy* and EPICC COVID-19 Cohort Study Group

Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.

Miller et al.
BMJ
January 2026
Authors and Affiliates
Natalie J Miller, Christina Baik, Joel W Neal, Fangdi Sun, Rafael Santana-Davila, Sylvia Lee, Keith D Eaton, Renato G Martins, Cristina Rodriguez, Heather Wakelee, Sukhmani K Padda, Elena Sotillo, Eric Q Konnick, Alex Camai, Tatyana Pisarenko, Viswam S Nair, Crystal Mackall, A McGarry Houghton, Shin-Heng Chiou, Diane Tseng

HLA-A*03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

Zhang BC, et al.
EBio Medicine
September 2025
Authors and Affiliates
Brian C. Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, Beatrice Pignolet, Simon Falk, Christian Wünsch, Marie Deffner, Erik Yusko, Damon May, Daniel Mattox, Eva Dawin, Lisa Ann Gerdes, Florence Bucciarelli, Lisa Revie, Gisela Antony, Sven Jarius, Christiane Seidel, Makbule Senel, Stefan Bittner, Felix Luessi, Joachim Havla, Matthias Knop, Manuel A. Friese, Susanne Rothacher, Anke Salmen, Fumie Hayashi, Roland Henry, Stacy Caillier, Adam Santaniello, University of California San Francisco MS-EPIC Team, German Competence Network Multiple Sclerosis (KKNMS), Maria Seipelt, Christoph Heesen, Sandra Nischwitz, Antonios Bayas, Hayrettin Tumani, Florian Then Bergh, Gerd Meyer zu Hörste, Tania Kümpfel, Catharina C. Gross, Brigitte Wildemann, Martin Kerschensteiner, Ralf Gold, Sven G. Meuth, Frauke Zipp, Bruce A. C. Cree, Jorge Oksenberg, Michael R. Wilson, Stephen L. Hauser, Scott S. Zamvil, Luisa Klotz, Roland Liblau.

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

Derman BA, et al.
Hemasphere
August 2025
Authors and Affiliates
Benjamin A. Derman1 | Jennifer Cooperrider1 | Anna Pula1,2 | Heidi Simmons3 | Tadeusz Kubicki1,4 | Jeffrey Zonder5 | Aimaz Afrough6 | David Grinblatt7 | Jacalyn Rosenblatt8 | Larry D. Anderson Jr.6 | Andrew Kin5 | David Avigan6 | Sunil Narula1 | Shayan Rayani1 | Ken Jiang1 | Ajay Major9 | Theodore Karrison1 | Allison Jacob3 | Andrzej J. Jakubowiak1 1University of Chicago, Chicago, Illinois, USA 2Department of Hematology, Medical University of Lodz, Łódź, Poland 3Adaptive Biotechnologies, Seattle, Washington, USA 4Poznan University of Medical Sciences, Poznan, Poland 5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA 6Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA 7Endeavor Health, Evanston, Illinois, USA 8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA 9University of Colorado, Denver, Colorado, USA

Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis

Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2, Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3, Giada Bianchi1,2,3* 1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Previous Next